Credit: ZEISS
The Singapore Eye Research Institute (SERI) and Carl Zeiss Meditec have entered into a strategic partnership to advance surgical outcomes in refractive and cataract surgeries.
The collaboration, OPhthalmic Tech Innovation by ZEISS and SERI (OPTIZS), brings together cutting-edge expertise at a combined funding of nearly SG$20 million supported under Singapore’s Research, Innovation and Enterprise 2025 Plan (RIE 2025).
ZEISS and SERI will work jointly “to develop more personalized solutions and to enhance processes before and during surgery, so that patients can enjoy faster visual rehabilitation and better long-term stability after their surgeries.” They will also work on providing new options for treating presbyopia and improving outcomes for patients with myopia and presbyopia, with the aim of developing more advanced procedures.
“We look forward to the next three years as we embark on this exciting journey to develop novel surgical and diagnostic solutions. We hope that these culminate in better visual outcomes for our patients not only in the short term but in the long term too, and thereby, a better quality of life,” said Professor Jodhbir Mehta, Executive Director at SERI, and Program Lead for OPTIZS.”
